Enzyme News and Research

RSS

New anti-inflammatory strategy for cancer therapy

A new strategy for cancer therapy, which converts the tumor-promoting effect of the immune system’s inflammatory response into a cancer-killing outcome, is suggested in research findings by investigators at the University of California, San Diego (UCSD) School of Medicine.

20 Sep 2004

New Australian biotech speeds up healing for burns and wounds

A Queensland PhD student’s discovery speeds up tissue growth and repair and sparks off a new listed biotech company.

20 Sep 2004

Resveratrol in red wine, is thought to contribute to improved cardiovascular effects associated with moderate consumption of red wine

Researchers funded by the National Science Foundation (NSF) and affiliated with the Salk Institute in San Diego, Calif., have succeeded in converting chalcone synthase, a biosynthetic protein enzyme found in all higher plants, into an efficient resveratrol synthase.

20 Sep 2004

Protein points to anticancer drug targets

A unique tail at one end of a protein called Ubc12 stabilizes a molecular workshop that assembles the “on-switch cells” used to accelerate cell replication.

20 Sep 2004

New oral gel used instead of injection to deliver drugs

Scientists in India have developed a new gel that is taken orally and is capable of delivering drugs to manage diseases often requiring an injection.

20 Sep 2004

Further study is needed before link between gastroesophageal reflux disorder and otitis media can be firmly established

Does gastroesophageal reflux disorder (GERD) lead to middle ear infections in young children? Otitis media (OM) or ear infection, has the highest incidence, 62.9 percent, among all medical conditions in children younger than age five. Recent studies have suggested that GERD may cause OM.

18 Sep 2004

Significant relationships between laryngopharyngeal reflux and upper airway sensory impairment

Medical researchers have long suspected a relationship between gastro-esophageal reflux disease (GERD) and obstructive sleep apnea (OSA), two medical conditions which can have a deleterious effect on a patient¡¯s quality of life.

17 Sep 2004

Neck surgeons brush up on West Nile virus

Neck Surgery Foundation Annual Meeting & OTO EXPO, being held September 19-22, 2004, at the Jacob K. Javits Convention Center, New York City, NY.

17 Sep 2004

Slimming agents could pose major health risk

Commonly used nutritional supplements and body-building agents for elite athletes could pose an increased risk of cancer according to a study undertaken at the University of Sydney.

16 Sep 2004

RNAi enlisted in hunt for prawn vaccines

CSIRO researchers are using a biological phenomenon called RNA interference (RNAi) in an effort to develop a major biotechnological breakthrough for the aquaculture industry - vaccines for common prawn diseases.

16 Sep 2004

Celacade shown to reduce risk of death and hospitalization in patients with advanced chronic heart failure

Vasogen has announced that comprehensive results from the Company's phase II trial of Celacade (immune modulation therapy) in advanced chronic heart failure patients were published in the September 15 issue of the Journal of the American College of Cardiology (JACC).

16 Sep 2004

Drug combo may have a greater impact on cancer development

Cancer researchers have long suggested that new targeted drugs may work best when paired with other therapies. In a new study published today in Cancer Research, scientists have taken some of the first steps to demonstrate this synergy in mouse and cell line models.

16 Sep 2004

First molecular-scale images of DNA binding to an adenovirus enzyme

The images, which appear on the cover of the October 2004 issue of Molecular and Cellular Proteomics, show how binding to DNA may stimulate the enzyme and are already being used to design new antiviral drugs to block this interaction.

14 Sep 2004

Grant to study genetics and drug interaction

A University of Minnesota researcher received a nearly $1 million grant from the National Institutes of Health (NIH) to study how genetic differences affect whether people will experience dangerous drug interactions and how to adjust medications to avoid those interactions.

10 Sep 2004

Disruption of protein folding causes neurodegeneration, mental retardation

Excess accumulation in brain cells of a fat molecule called GM1-ganglioside (GM1) disrupts the folding of newly assembled proteins into their proper shapes, triggering nerve degeneration and mental retardation in children.

10 Sep 2004

Chemical pathways of serotonin in the nervous system pave way for future pharmaceutical treatments for depression

From mollusks to mammals, newly discovered chemical pathways of serotonin in the nervous system are paving a path toward future pharmaceutical treatments for depression and other disorders.

10 Sep 2004

Ramipril reduces rate of sudden cardiac death and nonfatal cardiac arrest by 21 percent

Ramipril, a high blood pressure and heart failure drug, can reduce the rate of sudden cardiac death and nonfatal cardiac arrest by 21 percent in people at high risk for heart attack or stroke, according to a study reported in Circulation: Journal of the American Heart Association.

7 Sep 2004

Researchers have successfully produced small quantities of a new vaccine for anthrax using Bacillus bacteria

Tiny types of soil bugs already make many of the products we use in washing detergents, foods, and waste treatment, but scientists now hope that similar bacteria will also make the vaccines and drugs of the future

7 Sep 2004

New way of killing dangerous bacteria like the ones which cause anthrax and pneumonia

The new bug-smashing technique uses the bacteria’s own natural enemies, tiny viruses called bacteriophages (or phages), which can infect bacterial cells. The phages make thousands of copies of themselves inside infected bacteria, but then need to dissolve the bacteria’s cell wall to get out and infect other bacterial cells.

7 Sep 2004

Generic tritherapy can be used as a basic treatment for AIDS

A clinical trial, conducted in Cameroon by IRD researchers working with other organizations and supported by the ANRS, has demonstrated that one of the most common combinations currently deployed in Africa, using nevirapine, stavudine and lamivudine, satisfies these criteria.

5 Sep 2004

Enzyme News and Research

New anti-inflammatory strategy for cancer therapy

New Australian biotech speeds up healing for burns and wounds

Resveratrol in red wine, is thought to contribute to improved cardiovascular effects associated with moderate consumption of red wine

Protein points to anticancer drug targets

New oral gel used instead of injection to deliver drugs

Further study is needed before link between gastroesophageal reflux disorder and otitis media can be firmly established

Significant relationships between laryngopharyngeal reflux and upper airway sensory impairment

Neck surgeons brush up on West Nile virus

Slimming agents could pose major health risk

RNAi enlisted in hunt for prawn vaccines

Celacade shown to reduce risk of death and hospitalization in patients with advanced chronic heart failure

Drug combo may have a greater impact on cancer development

First molecular-scale images of DNA binding to an adenovirus enzyme

Grant to study genetics and drug interaction

Disruption of protein folding causes neurodegeneration, mental retardation

Chemical pathways of serotonin in the nervous system pave way for future pharmaceutical treatments for depression

Ramipril reduces rate of sudden cardiac death and nonfatal cardiac arrest by 21 percent

Researchers have successfully produced small quantities of a new vaccine for anthrax using Bacillus bacteria

New way of killing dangerous bacteria like the ones which cause anthrax and pneumonia

Generic tritherapy can be used as a basic treatment for AIDS

Biochemistry eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo